HKHannah Kibuuka

Hannah Kibuuka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hannah Kibuuka has a total of 207 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Factors associated with viral suppression and antiretroviral therapy adherence among adolescents and young adults living with HIV in the African Cohort Study

    by Marie A. Brault, Aima A. Ahonkhai, Seth Frndak, Susannah Colt, Trevor A. Crowell, Ajay Parikh, Emma R. Duff, Valentine Sing’OEi, John Owuoth, Jonah Maswai, et al.

    Introduction: Adolescents and young adults living with HIV (AYLHIV) experience poor outcomes across the care continuum, and most reside in sub-Saharan Africa. The African Cohort Study (AFRICOS) provides an opportunity to examine HIV outcomes in this population across Kenya, Nigeria, Tanzania, and Uganda. Methods: We conducted a cross-sectional analysis of AYLHIV aged 15–29 years, enrolled in AFRICOS 2013-2023, and on antiretroviral therapy (ART) ≥ six months. Primary outcomes were HIV viremia and 30-day ART non-adherence. Factors included HIV acquisition route, ART duration, ART class, and site. We used multivariate robust Poisson regression to estimate relative risks (RRs) and 95% confidence intervals (CIs). Site directors were surveyed to assess youth-friendly services. Results: Among 656 participants, the median age was 20.0 years (IQR 17.5–23.3); 41.6% were male, 61.6% had perinatally-acquired HIV, and median duration since HIV diagnosis was nine years. At enrollment, 83.8% had viral suppression (<200 copies/mL) and 80.2% were ART adherent. ART regimen and clinic site were associated with viral suppression: youth on integrase vs. protease inhibitor-based regimens (adjusted relative risk (aRR) 0.38, CI 0.23–0.63, p<0.001), and in Uganda (aRR 0.42, CI 0.20–0.90, p=0.026) or Kisumu, Kenya (aRR 0.40, CI 0.22–0.76, p=0.005) had lower likelihood of non-suppression. Compared to Nigeria, participants from other sites were less likely to report non-adherence (unadjusted RR 0.31-0.44). Youth-friendly service provision varied. Conclusions: Viral suppression and ART adherence were high among AYLHIV in AFRICOS. Clinic site and ART regimen were associated with outcomes, highlighting the importance of health system factors.


  • Open Access

    Likelihood of Blood Culture Positivity Using SeptiCyte RAPID

    by Krupa A. Navalkar, Alyse Wheelock, Melissa Gregory, Danielle V. Clark, Hannah Kibuuka, Stephen Okello, Sharon Atukunda, Abdullah Wailagala, Peter Waitt, Francis Kakooza, et al.

    Background: Early diagnosis and identification of causative pathogens using blood culture in patients suspected of blood stream infection (BSI) and sepsis are critical for improving patient outcomes through earlier and more targeted treatment. There is a need for tools that can guide the use of microbiologic diagnostics, especially where resources are limited, such as in lower- and middle-income countries (LMICs), pandemic and mass-casualty scenarios, and prolonged field care settings during military operations. Methods: Post hoc retrospective analysis of individual patient data from three prospective clinical studies, conducted in North America, Europe and Africa, to investigate the association between SeptiCyte RAPID test results (SeptiScores) and blood culture (BC) results. Hypothesis: that a significant correlation exists between elevated SeptiScores and positive blood culture results, and between low SeptiScores and negative blood culture results. Results: The area under the receiver operating characteristic curve (ROC AUC) was 0.91 for 85 BC(+) versus 257 SIRS and was 0.80 for 164 BC(−) versus 257 SIRS. As the SeptiScore increases, the relative probability of a septic patient being BC(+) as opposed to BC(−) also increases. A non-linear positive correlation is observed. Below a crossover point at SeptiScore 10, the ratio of probabilities of BC(+) sepsis/BC(−) sepsis is 1. Thus, septic patients with SeptiScores >10 have a higher probability of being BC(+) compared to BC(−). Conclusions: Elevated SeptiScores, obtained before blood culture results, are indicative of increased blood culture positivity. This may have clinical utility, particularly in resource-limited settings, as an aid for improving the efficiency of blood culture practice, for instance, by informing patient selection and interpretation of blood culture results.


  • Open Access

    Finding the Sweet Spot: Preferences for Effectiveness, Duration, and Side Effects in a Discrete Choice Experiment Among Uganda’s Key Populations

    by Maiya G. Block Ngaybe, Richard Muhumuza, Mélanie Antunes, Ezra Musingye, Kawoya Kijali Joseph, Betty Nakaggwa, Stephen Mugamba, Bashir Ssuna, Gabriela Valdez, John Ehiri, et al.

    Background: Human immunodeficiency virus (HIV) affects more than 39 million people worldwide, with Uganda ranked 10th among countries with the highest number of cases. As new preventative HIV injectables emerge, it is vital to think about how best to tailor strategies to promote these injectable drugs, like PrEP and vaccines, when available, to the different populations most in need. Discrete choice experiments (DCEs) are economics-derived methods used to determine factors that influence engagement in a certain behavior. Objective: This study used a DCE to determine the preferences for a preventative HIV injectable drugs/vaccines among people at risk of HIV acquisition in urban and peri-urban areas of Uganda. Methods: In June 2024, we implemented a cross-sectional DCE survey in three urban sites in Uganda in English and Luganda. The survey collected information on demographics, HIV risk, vaccine confidence and responses to the 13 injection product choice tasks presented to determine preferences. We used community-based, respondent-driven sampling methods to recruit participants from three key populations: (1) female sex workers; (2) people who identify as lesbian, gay, bisexual or transgender; and (3) young women (18–24 years). We collected the data on tablets using the Sawtooth Lighthouse Studio software (v. 19.15.6), taking into consideration privacy and confidentiality, given the sensitivity of the information and recent governmental policies in Uganda. Data were analyzed using a split-sample mixed logit regression analysis. The study was approved by local ethical regulatory bodies. Results: From the total of 406 participants screened for this study, 376 participants met the eligibility criteria and were included in the final analysis (85 young women, 159 female sex workers, and 132 who identified as lesbian, gay, bisexual or transgender). The average age was 23.7 (SD: 5.7). The majority of participants had received some secondary school or vocational school (202, 53.7%) The attributes that explained the preferences were primarily severe compared to mild side effects (β: −0.69, 95% CI: −0.78, −0.60), a 30% increase in vaccine/drug effectiveness (β: 0.39, 95% CI: 0.34, 0.44), and a 50,000 UGX (or USD ~13.64) increase in cost (β: −0.22, 95% CI: −0.27, −0.17). There were no significant differences between the preferences for different injectable types. The sensitivity analyses suggested potential differences in preferences by the amount of help participants received from research assistants when completing the survey, although not by income level. Conclusions: Side effects had the greatest impact on participants’ preferences for injectable HIV prevention methods, followed closely by effectiveness and cost. It is therefore essential to develop affordable or free prevention options with minimal side effects. Policymakers should focus on reducing the financial barriers to access and emphasize transparent communication about the effectiveness and safety of these injectables in health promotion campaigns to maximize adoption and improve public health outcomes.


  • Open Access

    Likelihood of blood culture positivity using SeptiCyte RAPID

    by Krupa Navalkar, Alyse Wheelock, Melissa Gregory, Danielle Clark, Hannah Kibuuka, Stephen Okello, Sharon Atukunda, Abdullah Wailagala, Peter Waitt, Francis Kakooza, et al.

    Early diagnosis and identification of causative pathogens using blood culture in patients suspected of Blood Stream Infection (BSI) and sepsis are critical for improving patient outcomes through early and more targeted treatment. Methods Post-hoc retrospective analysis of indiviudal patient data from three prospective clinical studies, conducted in North America, Europe and Africa, to investigate the association between SeptiCyte RAPID test results (SeptiScores) and blood culture results. Hypothesis that a significant correlation exists between elevated SeptiScores and positive blood culture results, and between low SeptiScores and negative blood culture results. Results As the SeptiScore increases, the relative probabilty of a septic patient being BC(+) as opposed to BC(−) also increases. A non-linear positive correlation is observed. Below SeptiScores of 10, the ratio of probabilities of BC(+) sepsis / BC(−) sepsis is 1. Thus, septic patients with SeptiScores >10 have a higher probability of being BC(+) compared to BC(−). Conclusions Elevated SeptiScores, obtained before blood culture results, are indicative of increased blood culture positivity. This may have clinical utility, particularly in resource limited settings, as an aid for improving the efficiency of blood culture practice, for instance by informing patient selection and interpretation of blood culture results.

  • Open Access

    The Transformative Impact of the African Cohort Study (AFRICOS) Toward Reaching HIV 95-95-95 Goals in Sub-Saharan Africa

    by Neha Shah, Trevor A. Crowell, Jaclyn Hern, Victor Anyebe, Emmanuel Bahemana, Hannah Kibuuka, Valentine Singoei, Jonah Maswai, Ajay Parikh, Emma R. Duff, et al.

    : Over the last 20 years, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) has rapidly expanded and made remarkable progress toward the UNAIDS 95-95-95 targets to end the HIV epidemic. Nevertheless, HIV continues to pose a significant health challenge globally, with a particular impact on the African continent. Funded by PEPFAR, the African Cohort Study (AFRICOS) has served as a monitoring and evaluation tool for PEPFAR to help guide HIV policy and PEPFAR programming for the last 10 years since its inception and offers a compelling example of how PEPFAR’s investment in science continues to reap dividends. This paper details and critically reviews the transformative research AFRICOS has had on helping to end the HIV epidemic as a public health threat by 2030.


  • Open Access

    Exploring HIV Prevention Preferences Among Key Populations in Uganda: A Qualitative Study

    by Maiya G Block Ngaybe, Kawoya Kijali Joseph, Wadana Hamzazai, Carly Jo Deal, Stephen Mugamba, Wambi Moses Stephen, Richard Muhumuza, Betty Nakaggwa, Auwal Abubakar, Gabriela Valdez, et al.

    Background/Objectives: Long-acting injectable pre-exposure prophylaxis (PrEP) has recently been approved for use, and dissemination, but has yet to be released in Uganda. To ensure uptake of this injectable option, and others like a future HIV vaccine, it is important to understand the preferences of the populations at the highest risk who will benefit the most. We present data on product preferences for HIV prevention practices and injectable HIV prevention among populations most at risk for HIV with a focus on injectable options such as long-acting PrEP or a future HIV Vaccine for primary prevention of HIV. Methods: In March 2024, we conducted 20 semi-structured key informant interviews in English and Luganda among 10 experts in the field of HIV prevention, and 10 peer leaders of key or priority populations in Uganda. Participants were purposively selected to represent various groups, genders, occupations and locations to get diverse perspectives. Both groups of participants were asked similar questions, with experts focusing on their experience with key populations. Debriefs were held after each interview to monitor emerging themes and assess data saturation. Data were analyzed using a thematic analysis guided by Lancaster’s consumer theory. Results: The most common prevention practices mentioned by participants were condoms and PrEP. Participants mentioned barriers to prevention practices including duration, accessibility issues such as transportation, location issues and stigma. The most important characteristics for participants when considering the uptake of a new injectable prevention product included efficacy, cost and side effects. Experts tended to have higher minimal acceptable efficacy percentages. Participants who were peer leaders recognized that some had a fear of needles, though they also expressed motivation to receive injections due to the perception that they may work better than other modes of administration. Conclusions: According to experts and peer leader participants in this study, key populations in Uganda prefer high efficacy, lower side effects and confidentiality in their services. Participants emphasized the need for comprehensive and accessible information about specific HIV prevention methods to improve the uptake of these products. Tailored messaging and choice can accommodate the heterogeneity of preferences to best ensure HIV prevention in Uganda.

  • Open Access

    Advanced HIV disease in East Africa and Nigeria, in The African Cohort Study

    by Ikwo K. Oboho, Allahna L. Esber, Nicole Dear, Heather N. Paulin, Michael Iroezindu, Emmanuel Bahemana, Hannah Kibuuka, John Owuoth, Jonah Maswai, Neha Shah, et al.

    Background: Earlier antiretroviral therapy (ART) may decrease progression to advanced HIV disease (AHD) with CD4 count of P <0.001). Factors associated with higher odds of CD4 count of <200 cells per cubic millimeter were male sex (adjusted odds ratio 1.56 [confidence interval: 1.29 to 1.89]), being 30–39 years (1.42 [1.11–1.82]) or older (compared with <30), have World Health Organization stage 2 disease (1.91 [1.48–2.49]) or higher (compared with stage 1), and HIV diagnosis eras 2013–2015 (2.19 [1.42–3.37]) or later (compared with <2006). Compared with ART-naive, unsuppressed participants, being viral load suppressed on ART, regardless of ART duration, was associated with lower odds of CD4 count of <200 cells per cubic millimeter (<6 months on ART: 0.45 [0.34–0.58]). Conclusion: With ART scale-up, AHD has declined. Efforts targeting timely initiation of suppressive ART may further reduce AHD risk.


  • Open Access

    Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study

    by Adeep Puri, Andrew J. Pollard, Catherine Schmidt-Mutter, Fabrice Lainé, George PrayGod, Hannah Kibuuka, Houreratou Barry, Jean-François Nicolas, Jean-Daniel Lelièvre, Sodiomon Bienvenu Sirima, et al.

    In this prospective, observational study (ClinicalTrials.gov Identifier: NCT02661464), long-term safety information was collected from participants previously exposed to the Ebola vaccines Ad26.ZEBOV and/or MVA-BN-Filo while enrolled in phase 1, 2, or 3 clinical studies. The study was conducted at 15 sites in seven countries (Burkina Faso, France, Kenya, Tanzania, Uganda, the United Kingdom, and the United States). Adult participants and offspring from vaccinated female participants who became pregnant (estimated conception ≤28 days after vaccination with MVA-BN-Filo or ≤3 months after vaccination with Ad26.ZEBOV) were enrolled. Adults were followed for 60 months after their first vaccination, and children born to female participants were followed for 60 months after birth. In the full analysis set (n = 614 adults; median age [range]: 32.0 [18–65] years), 49 (8.0%) had ≥1 serious adverse event (SAE); the incidence rate of any SAE was 27.4 per 1000 person-years (95% confidence interval: 21.0, 35.2). The unrelated SAEs of malaria were reported in the two infants in the full analysis set, aged 11 and 18 months; both episodes were resolved. No deaths or life-threatening SAEs occurred during the study. Overall, no major safety issues were identified; one related SAE was reported. These findings support the long-term clinical safety of the Ad26.ZEBOV and MVA-BN-Filo vaccines.


  • Open Access

    Genome Analysis of Klebsiella pneumoniae Reveals International High-Risk Pandemic MDR Clones Emerging in Tertiary Healthcare Settings in Uganda

    by Denis K. Byarugaba, Bernard Erima, Godfrey Wokorach, Stephen Alafi, Hannah Kibuuka, Edison Mworozi, Florence Najjuka, James Kiyengo, Ambrose K. Musinguzi, Fred Wabwire-Mangen

    Klebsiella pneumoniae is a threat to public health due to its continued evolution. In this study, we investigated the evolution, convergence, and transmission of hypervirulent and multi-drug resistant (MDR) clones of K. pneumoniae within healthcare facilities in Uganda. There was high resistance to piperacillin (90.91%), cefuroxime (86.96%), ceftazidime (84.62%), cefotaxime (84.00%), amoxicillin/clavulanate (75%), nalidixic acid (73.68%), and nitrofurantoin (71.43%) antibiotics among K. pneumoniae isolates. The isolates were genetically diverse, consisting of 20 different sequence types (STs) and 34 K-serotype groups. Chromosomal fosA (for fosfomycin) and oqxAB efflux pump genes were detected in all isolates. Two carbapenem resistance genes, blaNDM-5 and blaOXA-181 plus extended-spectrum beta-lactamase (blaCTX-M-15) gene (68.12%), quinolone-resistant genes qnrS1 (28.99%), qnrB1 (13.04%), and qnrB6 (13.04%) and others were found. All, except three of the isolates, harbored plasmids. While the isolates carried a repertoire of virulence genes, only two isolates carried hypervirulent genes demonstrating a low prevalence (2.90%) of hypervirulent strains. Our study demonstrated genetically diverse populations of K. pneumoniae, low levels of carbapenem resistance among the isolates, and no convergence of MDR and hypervirulence. Emerging high-risk international pandemic clones (ST11, ST14, ST147, ST 86 and ST307) were detected in these healthcare settings which are difficult to treat.


  • Open Access

    Whole Genome Sequencing Reveals High Genetic Diversity, Diverse Repertoire of Virulence-Associated Genes and Limited Antibiotic Resistance Genes among Commensal Escherichia coli from Food Animals in Uganda

    by Denis K. Byarugaba, Godfrey Wokorach, Stephen Alafi, Bernard Erima, Florence Najjuka, Edison A. Mworozi, Hannah Kibuuka, Fred Wabwire-Mangen

    Commensal Escherichia coli with broad repertoire of virulence and antimicrobial resistance (AMR) genes pose serious public health risks as reservoirs of AMR and virulence. This study undertook whole genome characterization of commensal E. coli from food-producing animals in Uganda to investigate their genome variability (resistome and virulome). We established that the E. coli had high genomic diversity with 38 sequence types, 24 FimH types, and 33 O-antigen serotypes randomly distributed within three phylogroups (A, B1, and E). A greater proportion (≥93.65%) of the E. coli were resistant to amoxicillin/clavulanate and ampicillin antibiotics. The isolates were AmpC beta-lactamase producers dominated by blaEC-15 (71.88%) and tet(A) (20.31%) antimicrobial resistant genes besides a diverse armory of virulence-associated genes in the class of exotoxin, adhesins, iron uptake, and serine protease autotransporters which varied by host species. Cattle were found to be the major source of E. coli carrying Shiga toxin genes, whereas swine was the main source of E. coli carrying colicin-like Usp toxin gene. The study underscores the importance of livestock as the carrier of E. coli with antimicrobial resistance and a large repertoire of virulence traits with a potential of causing disease in animals and humans by acquiring more genetic traits.